Could tumour necrosis factor blockers inhibit the progression of future structural damage in ankylosing spondylitis?
作者信息
Gaspersic N, Sersa I, Jevtic V, Tomsic M, Praprotnik S
出版信息
Ann Rheum Dis. 2008 Sep;67(9):1354. doi: 10.1136/ard.2007.082537.
PMID:18697784
Abstract
摘要
相似文献
1
Could tumour necrosis factor blockers inhibit the progression of future structural damage in ankylosing spondylitis?
Ann Rheum Dis. 2008 Sep;67(9):1354. doi: 10.1136/ard.2007.082537.
2
[New results from studies of therapy of ankylosing spondylitis with infliximab].
Z Rheumatol. 2003 Apr;62(2):108-9. doi: 10.1007/s00393-003-0501-3.
3
Treatment of ankylosing spondylitis with infliximab.
Ann Rheum Dis. 2001 Dec;60(12):1159-60. doi: 10.1136/ard.60.12.1159.
4
Antitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients.
Ann Rheum Dis. 2013 Jul;72(7):1265-7. doi: 10.1136/annrheumdis-2012-203169. Epub 2013 Mar 12.
5
Evidence in support of the validity of the TNF brake hypothesis.
Ann Rheum Dis. 2013 Dec;72(12):e31. doi: 10.1136/annrheumdis-2013-204485. Epub 2013 Aug 29.
6
Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation.
Ann Rheum Dis. 2007 Jan;66(1):133-4. doi: 10.1136/ard.2006.057745.
7
Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab.
Ann Rheum Dis. 2005 Oct;64(10):1462-6. doi: 10.1136/ard.2004.033472. Epub 2005 Mar 18.
8
Response to 'Evidence in Support of the Validity of the TNF Brake Hypothesis' by Maksymowych.
Ann Rheum Dis. 2013 Dec;72(12):e32-3. doi: 10.1136/annrheumdis-2013-204493. Epub 2013 Sep 20.
9
Anti-tumour necrosis factor therapy in ankylosing spondylitis. A need for guidelines.
Rheumatology (Oxford). 2003 Mar;42(3):490. doi: 10.1093/rheumatology/keg113.
10
Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.
Ann Rheum Dis. 2008 May;67(5):729-30. doi: 10.1136/ard.2007.077370.
Zotero 插件